A phase 1 study of Flavivirus vaccine (EMX-001).
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2018
Price : $35 *
At a glance
- Drugs EMX-001 (Primary)
- Indications Dengue; Yellow fever; Zika virus infection
- Focus Adverse reactions
- 20 Sep 2018 According to an Emergex Vaccines media release, company Enters into MoU with Brazils Fiocruz. The first part is a Collaboration Agreement under which Fiocruz and Emergex will initially carry out this study.
- 02 Apr 2018 New trial record
- 26 Mar 2018 According to an Emergex Vaccines media release, company is planning to initiate this study in early 2019.